Chagas heart disease

Article written and reviewed by Dr Luca Moretti

Chagas heart disease is the cardiovascular manifestation of Trypanosoma cruzi infection and is a major cause of cardiomyopathy, arrhythmias and sudden death in many areas of Latin America. International mobility has brought the problem to Europe and North America as well, where it may remain unrecognized for decades; a history of birth or long-term residence in an endemic area retains clinical value even when the last exposure occurred in childhood.

Classic transmission occurs when feces or urine from infected triatomine bugs contaminate broken skin or mucous membranes, but congenital, oral, transfusional, transplantation and accidental routes also exist. The acute phase lasts for weeks, is characterized by high parasitemia and is often paucisymptomatic; the parasite subsequently persists in tissues at low density. After years or decades, some infected people develop heart disease, megacolon, megaesophagus or mixed forms.

The chronic indeterminate form is defined by serologically confirmed infection in the absence of clinical manifestations and the abnormalities specified by the classification being used. It does not imply sterility and does not guarantee that the disease will remain stable, but the annual risk of progression for an individual patient is relatively low. Periodic ECG and clinical assessment identify transition to the cardiac form before overt heart failure develops.

Chagas cardiomyopathy has a distinctive phenotype: segmental lesions, apical aneurysm, sinus-node and conduction disease, ventricular tachycardia, thromboembolism and autonomic dysfunction may precede global dilatation. The arrhythmia-heart failure-embolism triad determines prognosis and requires assessment that is not limited to ejection fraction.

Diagnosis is also an act of family health care; identifying an infected person may reveal siblings exposed in the same home, a mother at risk of congenital transmission or children who have never been screened, without implying ordinary person-to-person transmission. Counseling must avoid stigma and explain which relatives have a genuine epidemiologic probability and which routes of transmission do not occur in everyday life.

Risk is not confined to traditional rural housing because oral transmission in foodborne outbreaks, congenital transmission and population mobility continue to generate new cases even after major vector-control programs. Prevention must therefore combine housing improvement, triatomine control, food safety, blood and organ screening and maternal diagnosis, adapting interventions to the predominant route in the community.

Etiology, Pathogenesis and Pathophysiology

T. cruzi comprises genetic lineages and strains with different distributions and tissue tropism; trypomastigotes enter cells and transform into replicating amastigotes, which rupture the cell and spread. During the acute phase, parasitemia and tissue burden may cause diffuse myocarditis with edema, effusion and, rarely, shock.

During the chronic phase, the parasite does not disappear completely but persists in myocardial niches and other tissues with a focal distribution. Blood levels fluctuate below the detection threshold of direct methods, explaining why a negative PCR does not exclude infection; persistence provides a continuous antigenic stimulus and makes a model of autoimmunity completely separated from the pathogen inadequate.

Immunity controls parasite burden but damages the myocardium through T lymphocytes, macrophages, antibodies and cytokines. Patchy inflammation evolves toward interstitial and replacement fibrosis, particularly in inferolateral and apical regions; this heterogeneity creates channels of slow conduction that sustain monomorphic ventricular tachycardia.

Microcirculatory abnormalities, vasospasm, platelet aggregation and endothelial dysfunction produce repeated ischemia without obstructive coronary artery disease. Autonomic injury reduces parasympathetic neurons and alters heart-rate control and vasomotor regulation; no single mechanism explains the entire phenotype, which results from their interaction over time.

The conduction system is affected by inflammation and fibrosis, producing right bundle branch block, left anterior fascicular block, AV block and sinus-node dysfunction. The combination of right bundle branch block and left anterior fascicular block is suggestive in an exposed patient but is not diagnostic; progression may make pacing necessary independently of the degree of ventricular dysfunction.

A Chagas apical aneurysm may appear while global function is still preserved; the aneurysmal cavity contains slow flow, thrombi and arrhythmic circuits, whereas inferolateral aneurysms or aneurysms in other segments may be missed by conventional echocardiographic windows. Cardiac magnetic resonance and contrast echocardiography improve detection and quantification.

Advanced heart failure combines dilatation, right-ventricular dysfunction, mitral regurgitation and low output; compared with other cardiomyopathies with the same ejection fraction, arrhythmic and thromboembolic burden may be greater. Denervation and low blood pressure sometimes make standard therapy more difficult to titrate.

In immunocompromised patients, especially after transplantation, malignancy or advanced HIV infection, loss of cellular control causes reactivation with parasitemia, myocarditis, panniculitis or encephalitis. Reactivation is not simply an acceleration of chronic cardiomyopathy: it is a new replicative phase that requires direct demonstration and urgent treatment.

Progression is not uniform: some patients maintain a normal ECG for decades, whereas others develop conduction disturbances and scar early even without heart failure. Initial parasite burden, strain, reinfections, immune response and host factors contribute, but no single marker can predict individual transition; periodic follow-up therefore remains more reliable than definitive reassurance after the first examination.

Repeated reinfection in areas with active transmission may increase parasitic stimulation, whereas in non-endemic countries progression generally occurs without new vector exposures. This difference influences prevention but does not eliminate already established persistence; individual treatment must be accompanied by environmental interventions when the patient continues to live in a high-risk dwelling.

Clinical Manifestations

The acute phase is often asymptomatic or causes fever, fatigue, lymphadenopathy, hepatosplenomegaly and edema; an inoculation chagoma and Romaña sign are suggestive but not required. Acute myocarditis with tachycardia, cardiomegaly, effusion and heart failure is more common in children or after oral transmission with a high inoculum.

During the early chronic phase, the ECG may be the first abnormal finding; palpitations, presyncope and syncope result from ectopy, tachycardia, sinus-node dysfunction or conduction block. Unexplained syncope is highly relevant because it may precede sudden death and requires prolonged monitoring or selected electrophysiologic study.

Ventricular tachycardia is often monomorphic and arises from inferolateral or apical scars, with a possible epicardial substrate. It may present as tolerated palpitations, electrical storm, syncope or cardiac arrest; amiodarone reduces recurrences in many patients but does not replace an ICD when a secondary-prevention indication exists.

Heart failure causes dyspnea, edema, ascites and exercise intolerance and may be worsened by bradycardia, tachycardia or chronic ventricular pacing. Right-sided congestion is common in advanced stages; low blood pressure and autonomic dysfunction may limit doses, requiring slow titration without prematurely abandoning effective therapies.

Stroke and systemic embolism may precede heart failure, especially in the presence of an apical aneurysm, thrombus, atrial fibrillation or severe ventricular dysfunction. Cryptogenic stroke in a person from an endemic area should prompt consideration of Chagas disease; thrombus detection requires contrast imaging or cardiac magnetic resonance when the apex is not well visualized.

Dysphagia, regurgitation, severe constipation and abdominal distension indicate gastrointestinal involvement and affect nutrition, absorption and procedures. Neuropathies and autonomic disorders complete the systemic picture; cardiac assessment should not ignore these organs because a mixed form may determine risk and quality of life.

Reactivation presents with fever, rising parasitemia and new cutaneous, neurologic or cardiac lesions. In transplant recipients, T. cruzi myocarditis may mimic rejection and requires serial PCR and expert biopsy interpretation; increasing immunosuppression without recognizing reactivation can be fatal.

Syncope is evaluated as a possible tachyarrhythmia, conduction block or autonomic dysfunction. A negative 24-hour Holter monitor does not exclude rare events and may be followed by longer monitoring or an implantable loop recorder when probability and consequences are high. Attributing loss of consciousness to chronic hypotension without documentation risks missing a sentinel sign of sudden death.

Chest pain may result from microvascular disease, arrhythmia, heart failure or concomitant coronary artery disease and is not automatically attributed to Chagas disease. Age and risk factors determine coronary investigation, while cardiac magnetic resonance distinguishes nonischemic scar from infarction; coexistence is possible and modifies prevention, antithrombotic therapy and prognosis.

Investigations and Diagnosis

Probability arises from the epidemiologic history across the entire lifetime; country and region of birth, type of housing, exposure to triatomine bugs, an infected mother, transfusions, foods involved in oral outbreaks and transplantation are relevant. Living today in a non-endemic country does not reduce a probability acquired decades earlier.

During the chronic phase, diagnosis generally requires two serologic tests using different antigens or principles because no single test has absolute accuracy. If results are discordant, a third method is performed; antibodies persist and do not distinguish the indeterminate form from cardiomyopathy.

During the acute phase, early congenital infection and reactivation, parasites are sought directly by microscopy, concentration methods or quantitative PCR. PCR is highly valuable for monitoring reactivation, but intermittent negativity during the chronic phase does not exclude infection; in newborns, transferred maternal antibodies require specific algorithms and timing.

The ECG looks for right bundle branch block, fascicular block, AV block, bradycardia, Q waves and ST-T abnormalities; a normal tracing defines a lower but not absent risk. Holter monitoring quantifies ectopy, nonsustained tachycardia, pauses and variability; implantable recorders are useful in intermittent syncope when the result would change treatment.

Echocardiography assesses chamber dimensions, biventricular function, segmental abnormalities, aneurysms and thrombi; contrast is important when the apex is poorly visualized. Cardiac magnetic resonance depicts fibrosis with late gadolinium enhancement and identifies aneurysms and thrombi, contributing to arrhythmic stratification and differential diagnosis.

Chest radiography, exercise testing and cardiopulmonary exercise testing assess cardiomegaly and functional capacity; coronary angiography is performed according to ischemic risk. Biopsy is not necessary in typical seropositive chronic cardiomyopathy but is fundamental when reactivation, rejection or another myocarditis is suspected and tissue findings would change therapy.

The Rassi score uses NYHA class III-IV, cardiomegaly, systolic dysfunction or segmental abnormalities, nonsustained ventricular tachycardia, low voltage and male sex to stratify mortality in validated cohorts. It is a complement rather than an individual verdict; it does not replace specific indications for an ICD, transplantation or anticoagulation.

The differential diagnosis includes dilated and arrhythmogenic cardiomyopathy, sarcoidosis, coronary artery disease and other causes of aneurysm. Positive serology may coexist with hypertension or ischemia; lesion distribution and the complete history define how much each process contributes to the phenotype.

Serologic screening in non-endemic countries must use tests validated in the relevant population and accessible confirmatory methods because a single result has consequences for therapy, pregnancy and donation. Discordance is not resolved by selecting the test with the higher value but by a third method and laboratory review; in the chronic phase, blood culture and smear lack sufficient sensitivity and a negative PCR does not eliminate the diagnosis.

Cardiac magnetic resonance quantifies fibrosis that is often more extensive than the visible segmental abnormalities and helps explain arrhythmias in the presence of relatively preserved function. The result does not replace Holter monitoring and the history of syncope but links anatomy to risk; in patients with devices, compatible protocols and other techniques are selected without abandoning assessment simply because a device is present.

Treatment and Prognosis

Benznidazole and nifurtimox are the two available trypanocidal drugs; efficacy is greatest in acute, congenital and recently acquired infection, and treatment is indicated during reactivation; in the early chronic phase it is generally offered after assessment. Age, advanced heart disease, pregnancy, renal and liver function and toxicity influence the decision and require national protocols.

The BENEFIT trial studied patients with established chronic Chagas cardiomyopathy: benznidazole increased conversion of blood PCR results but did not significantly reduce the composite of cardiac events during a mean follow-up of 5.4 years. This result does not negate benefit in earlier stages and does not mean parasitologic inefficacy; rather, it defines the limits of late treatment once scar has already formed.

Benznidazole may cause dermatitis, neuropathy, cytopenias and liver toxicity; nifurtimox frequently causes gastrointestinal adverse effects, weight loss and neurologic symptoms. Complete blood count, liver function, symptoms and adherence are monitored so that the course can be completed when safe; pregnancy requires postponement and strategies to prevent transmission in future pregnancies.

Heart failure is treated with guideline-directed therapies, recognizing that many trials included few patients with Chagas disease. Renin-angiotensin system blockade, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors and diuretics are adapted to blood pressure, renal function and congestion; bradycardia may limit beta-blockade and require an appropriate pacing strategy.

Pacemakers treat sinus-node dysfunction and symptomatic conduction block, whereas an ICD is indicated for secondary prevention after cardiac arrest or sustained tachycardia according to international principles. In primary prevention, ventricular function, syncope, nonsustained tachycardia and scar contribute to an individualized decision; amiodarone reduces arrhythmic burden but does not eliminate the risk of sudden death.

Ablation of ventricular tachycardia often requires both endocardial and epicardial approaches because of the inferolateral scar. It can reduce electrical storm and shocks but does not halt cardiomyopathy progression; mapping and imaging must protect the coronary structures and phrenic nerve in a complex substrate.

Anticoagulation is prescribed for atrial fibrillation, intracardiac thrombus, previous embolism or validated Chagas-specific risk profiles, balancing bleeding risk. Not every seropositive patient requires anticoagulation; regression of a thrombus does not necessarily eliminate risk when the aneurysm and stasis persist.

Heart transplantation provides effective therapy for advanced heart failure and, in some cases, refractory arrhythmias. Immunosuppression increases the risk of reactivation, which is controlled with serial PCR, biopsies and early treatment rather than universal prophylaxis in every protocol; Chagas etiology is not an automatic contraindication.

Prognosis depends on functional class, ventricular function, cardiomegaly, tachycardia, syncope, conduction blocks and thromboembolism. Sudden death may occur before terminal heart failure, while stroke affects independence and transplant candidacy; integrated follow-up identifies progression and applies devices and advanced therapies in time.

The decision to use trypanocidal therapy is shared after explaining the distinction between parasitologic cure and cardiac reversibility. A young person in the indeterminate phase has a different potential for benefit from that of an older patient with advanced scar, while reactivation and acute infection require urgent treatment. Presenting the BENEFIT trial as evidence that the parasite should never be treated, or promising that the drug will repair an aneurysm, are both incorrect interpretations.

Neurohormonal therapy is titrated carefully in view of frequently low blood pressure and bradycardia, avoiding confusion between limited tolerability and absence of benefit. A pacemaker can permit control of bradycardia, but dyssynchronous pacing should be minimized when cardiac function is impaired; cardiac resynchronization and physiologic conduction-system pacing are considered according to criteria and individual anatomy.

Complications

Sudden death results mainly from ventricular tachycardia or ventricular fibrillation, with a contribution from bradyarrhythmias. It may affect patients with relatively modest symptoms, making it important to investigate syncope and document nonsustained tachycardia; ICDs and ablation reduce specific risks without curing the underlying process.

Electrical storm requires antiarrhythmic drugs, sedation, correction of precipitating factors, ICD reprogramming and early ablation in refractory cases. Epicardial scar makes some exclusively endocardial procedures incomplete; repeated shocks worsen function and quality of life and require psychological support.

End-stage heart failure may be aggravated by right-ventricular dysfunction, mitral regurgitation and cardiorenal syndrome. Low blood pressure limits medications and sometimes delays referral for transplantation; advanced assessment should begin before cachexia and irreversible organ injury develop.

Apical thrombus, atrial fibrillation and stasis lead to stroke and systemic embolism. The aneurysm may be small but highly thrombogenic, so a nondiagnostic echocardiographic window requires contrast or cardiac magnetic resonance; antithrombotic prevention is individualized because bleeding risk is not negligible.

Reactivation during immunosuppression may cause rapidly progressive myocarditis, meningoencephalitis and skin lesions; an increase in PCR burden often precedes overt disease and allows pre-emptive therapy in transplant programs. A biopsy interpreted as rejection without searching for the parasite may lead to escalation in the opposite direction from that required.

Megacolon and megaesophagus cause malnutrition, aspiration, fecal impaction and difficulty absorbing medications. Surgery and nutritional therapy must be coordinated with cardiac risk and anticoagulation; management of chronic disease therefore extends beyond the cardiomyopathy.

Trypanocidal toxicity may interrupt potentially useful treatment, especially in adults; advance counseling, monitoring and early management of rash improve completion, whereas neurologic symptoms or cytopenias require immediate reassessment. New exposure remains possible and drug therapy does not replace vector control and food safety.

Congenital transmission is a preventable complication of missed maternal diagnosis; screening people at risk before pregnancy, treating infection outside pregnancy and testing the newborn interrupt the chain. Blood and organs must be screened according to epidemiology and local regulations.

Preconception counseling represents one of the most effective opportunities for prevention because treating an infected woman before pregnancy reduces the risk of future transmission, whereas benznidazole and nifurtimox are not administered during pregnancy. An exposed newborn follows a direct-testing algorithm during the first months and a serologic algorithm after maternal antibodies disappear, allowing highly effective cure when infection is recognized early.

For a patient living far from an expert center, a shared plan specifies the frequency of ECG, echocardiography and Holter monitoring and the criteria for referral, reducing travel without missing progression. Remote monitoring of implanted devices and collaboration with community care improve continuity, while trypanocidal drugs require pathways to manage rash, cytopenias and neurologic symptoms promptly. Quality of access influences outcomes as much as theoretical availability of therapies.

The diagnosis does not imply contagiousness through ordinary daily contact and should not lead to social or occupational exclusion; the relevant routes are vector-borne, congenital, transfusional, transplantation-related, oral and accidental. Accurate information reduces stigma and facilitates targeted family screening; the patient can participate in decisions about donation, pregnancy and treatment without being defined solely by an infection acquired many years earlier.

Lifelong follow-up does not mean indiscriminate repetition of the same tests but a schedule proportionate to ECG findings, cardiac function, symptoms and disease phase. A stable patient with indeterminate disease receives different surveillance from someone with an aneurysm, tachycardia or an implanted device, while any new immunosuppression activates a pathway for reactivation. This stratification concentrates resources where they can prevent events and keeps care accessible to populations that are often underserved.